Insider Selling: Blueprint Medicines Co. (NASDAQ:BPMC) Director Sells 15,161 Shares of Stock

Blueprint Medicines Co. (NASDAQ:BPMC) Director Jeffrey W. Albers sold 15,161 shares of Blueprint Medicines stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $109.53, for a total value of $1,660,584.33. Following the completion of the sale, the director now directly owns 152,396 shares in the company, valued at $16,691,933.88. This trade represents a 9.05 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Blueprint Medicines Trading Down 0.6 %

NASDAQ BPMC opened at $114.91 on Friday. The stock has a market cap of $7.30 billion, a PE ratio of -54.46 and a beta of 0.61. Blueprint Medicines Co. has a 12 month low of $72.24 and a 12 month high of $121.90. The company’s 50-day moving average price is $95.80 and its 200-day moving average price is $95.33. The company has a current ratio of 3.32, a quick ratio of 3.27 and a debt-to-equity ratio of 1.09.

Blueprint Medicines (NASDAQ:BPMC) last issued its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) EPS for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.08. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The business had revenue of $128.20 million for the quarter, compared to the consensus estimate of $127.56 million. During the same period in the prior year, the firm earned ($2.20) EPS. The company’s revenue for the quarter was up 126.5% compared to the same quarter last year. Equities research analysts forecast that Blueprint Medicines Co. will post -3.67 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on BPMC shares. Wedbush reaffirmed an “outperform” rating and issued a $124.00 price objective (down previously from $135.00) on shares of Blueprint Medicines in a research note on Monday, January 13th. UBS Group began coverage on shares of Blueprint Medicines in a research report on Thursday, October 24th. They set a “neutral” rating and a $88.00 price objective for the company. Guggenheim restated a “buy” rating on shares of Blueprint Medicines in a report on Wednesday, December 11th. HC Wainwright reaffirmed a “buy” rating and issued a $135.00 price target on shares of Blueprint Medicines in a report on Friday, November 15th. Finally, Stephens reiterated an “overweight” rating and issued a $140.00 price target on shares of Blueprint Medicines in a research report on Thursday, January 2nd. One analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $122.72.

Institutional Investors Weigh In On Blueprint Medicines

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Amalgamated Bank increased its stake in shares of Blueprint Medicines by 5.3% during the second quarter. Amalgamated Bank now owns 2,154 shares of the biotechnology company’s stock valued at $232,000 after buying an additional 109 shares during the period. Pallas Capital Advisors LLC increased its position in Blueprint Medicines by 3.2% during the 3rd quarter. Pallas Capital Advisors LLC now owns 5,657 shares of the biotechnology company’s stock valued at $523,000 after purchasing an additional 176 shares during the period. Clarus Wealth Advisors raised its holdings in shares of Blueprint Medicines by 8.6% in the 3rd quarter. Clarus Wealth Advisors now owns 2,590 shares of the biotechnology company’s stock valued at $231,000 after purchasing an additional 206 shares in the last quarter. Mackenzie Financial Corp lifted its position in shares of Blueprint Medicines by 5.2% in the 2nd quarter. Mackenzie Financial Corp now owns 4,885 shares of the biotechnology company’s stock worth $527,000 after purchasing an additional 243 shares during the period. Finally, Franklin Resources Inc. boosted its stake in shares of Blueprint Medicines by 0.7% during the third quarter. Franklin Resources Inc. now owns 36,761 shares of the biotechnology company’s stock valued at $3,259,000 after purchasing an additional 265 shares in the last quarter.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.